Physician profile
Tamara L Poling
NPI 1053357962
$6,574.97
in general payments reported to CMS, 2019-2025
21 companies · $712 in 2025
The $712 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $224 · 2021: $481 · 2022: $928 · 2023: $905 · 2024: $2,887 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753 · Travel and Lodging: $1,625 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.25 |
| Travel and Lodging | $1,624.87 |
| Education | $126.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,879.48 | 2019-2025 | |
| Allergan, INC. | $1,032.63 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $353.43 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $203.44 | 2020-2025 | |
| Janssen Biotech, INC. | $153.18 | 2020-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $133.72 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.09 | 2023-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $111.55 | 2019-2025 | |
| Galderma Laboratories, L.P. | $100.26 | 2019-2022 | |
| Pfizer INC. | $77.21 | 2020-2025 | |
| Lilly USA, LLC | $65.84 | 2019-2023 | Taltz |
| Amgen INC. | $53.78 | 2024-2025 | Otezla |
| Merck Sharp & Dohme LLC | $41.34 | 2019-2021 | |
| Kyowa Kirin, INC. | $36.38 | 2023 | Poteligeo |
| Ucb, INC. | $35.79 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33.60 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.11 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $32.70 | 2021 | |
| Janssen Scientific Affairs, LLC | $32.63 | 2024 | Tremfya |
| Mallinckrodt Hospital Products INC. | $26.35 | 2025 | Acthar |
| Vyne Pharmaceuticals INC. | $18.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.